

## CLAIMS

1. A combination product comprising a positive oil in water emulsion wherein said emulsion comprises a compound presenting free  $\text{NH}_2$  groups, at its natural state, at the oil-water interface, and an antibody, wherein said compound is linked to said antibody by a heterobifunctional linker, linking said  $\text{NH}_2$  groups to SH groups on the antibody hinge region.
2. The combination product of claim 1 wherein said product has a positive zeta charge.
3. The combination product of claim 1 or 2, wherein said compound presenting  $\text{NH}_2$  free groups is at least one cationic lipid selected from the group consisting of a  $\text{C}_{10}$ - $\text{C}_{24}$  alkylamine, a  $\text{C}_{10}$ - $\text{C}_{24}$  alkanolamine and a cholesterol ester.
4. The combination product of claim 3, wherein said compound presenting  $\text{NH}_2$  free groups is stearylamine or oleylamine.
5. The combination product of any of claims 1 to 4, wherein said emulsion comprises colloid particles having an oily core surrounded by an interfacial film, wherein said interfacial film comprises said compound presenting free  $\text{NH}_2$  at its natural state, nonionic surfactant and an anionic surfactant or anionic lipid, wherein said colloidal particles have a positive zeta potential.

6. The combination product of 5, wherein said emulsion contains an active principle (drug).

7. The combination product of any of claims 1 to 6,  
5 wherein said antibody is a polyclonal antibody.

8. The combination product of any of claims 1 to 6,  
wherein said antibody is a monoclonal antibody selected  
from the group comprising native forms, synthetic forms,  
10 chimeric forms and humanized forms.

9. The combination product of any of claims 1 to 8,  
wherein said antibody targets an antigen present at the  
surface of a pathological cell.

15  
10. The combination product of any of claims 1 to 9,  
wherein said antibody targets a protein selected from the  
group comprising HER-2, H-ferritin, PSMA, mucins, MUC 1,  
CD 44 and retinal S-Ag.

20  
11. The combination product of any of claims 1 to 6 and 8  
to 10, wherein said antibody is AMB8LK antibody.

12. The combination product of any of claims 1 to 11,  
25 wherein said linker is chosen from N-1 stearyl-maleimide  
(SM), oleylmaleimide, succinimidyl trans-4-  
(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC) and  
succinimidyl 3-(2-pyridyldithio)propionate (SPDP).

30 13. A method for producing a combination product  
according to claim 1, comprising the steps of:

- a) optionally reducing an antibody in order to obtain free SH group on its hinge region,
- b) mixing a positive emulsion wherein said emulsion comprises a compound which, at its natural state, contains free  $\text{NH}_2$  groups, wherein said compound is linked to a heterobifunctional linker by said  $\text{NH}_2$  groups, with the antibody presenting free SH groups in order to obtain said combination product.

14. The method of claim 13, wherein said positive emulsion in step b) is obtained by:

- i. linking an linker to a free  $\text{NH}_2$  group naturally present on a compound that is used to obtained a positive emulsion, in order to obtain a modified compound,
- ii. mixing said modified compound, which at its natural state contains free  $\text{NH}_2$  groups, with the other products necessary to obtain an emulsion, in order to obtain a positive emulsion.

15. The method of claim 13, wherein said positive emulsion in step b) is obtained by:

- i. mixing a compound, which at its natural state contains free  $\text{NH}_2$  groups, with the other products necessary to obtain an emulsion, in order to obtain a positive emulsion,
- ii. linking a linker to a free  $\text{NH}_2$  group naturally present on said compound, in order to obtain a modified compound within said positive emulsion.